(CTN News) – According to a statement that was released by Novavax on Wednesday, it appears that the Food and Drug Administration (FDA) of the United States of America will shortly give the COVID-19 vaccine its final approval. On the basis of the assertion, they did.

More than twenty-one percent of Novavax’s shares increased in value throughout the early trading session as a direct result of the announcement.

Novavax did this in response to the announcement.

The Associated Press reported that the administration of presidential candidate Donald Trump had delayed the decision, which led to concerns that it had been postponed. Despite this, the Novavax fact that the decision had been delayed helped to make those concerns more manageable.

The only company in the United States that continues to sell a protein-based COVID-19 vaccine is Novavax. People are able to protect themselves against the virus by receiving this vaccine. Only in the event of a major emergency is it permitted to be used at this time.

When compared to the mRNA vaccines that Pfizer and Moderna have developed and that the FDA has approved for use in specific age groups, there is a substantial difference between the two vaccinations. The FDA has authorized the use of these vaccines in specified age groups.

A statement that was issued by the firm not too long ago says that the Food and Drug Administration has supposedly asked Novavax to collect additional clinical data from individuals who have received vaccines.

Immediately following the initial announcement, the company issued a second statement in which it stated that it was “engaging with the FDA expeditiously” with the intention of obtaining complete approval “as soon as possible.”

Even after it has been demonstrated that a health crisis has been resolved, vaccinations could still be removed from circulation in accordance with the policy that governs the use of vaccines in emergency situations. After a health emergency has been handled, a product that has been completely approved by the Food and Drug Administration (FDA) is permitted to continue to be sold on the market.

The FDA has given their approval for this. Around the month of May in the year 2023, the World Health Organization (WHO) announced that the COVID situation would be resolved forever.

FDA approval was expected in April.

According to the Associated Press, Dr. Sara Brenner, who is now serving as the acting Commissioner of the Novavax, Food and Drug Administration, has provided the FDA with instructions to postpone the decision.

This resulted in an increase in the level of anxiety that the delay could have been induced by the American Health Secretary, Robert F. Kennedy Jr., who has been an opponent of vaccines for a very long time. As a result, confusion on the cause of the delay became more widespread.

Recently, Dr. Peter Marks, who had been serving as the chief of the vaccine division at the Food and Drug Administration (FDA), resigned from his position as a result of a disagreement with Kennedy on the safety of vaccines.

The COVID vaccines, which are administered in the United States, are designed to teach the body to recognize the tell-tale spike protein that is characteristic of the SARS-CoV-2 virus. This should be the primary objective of the vaccines.

In the Novavax vaccination, replicas of the spike protein that have been generated in a laboratory are coupled with a chemical that helps strengthen the immune system while the vaccine is being administered. This particular mix is what’s responsible for the vaccine’s effectiveness.

Both Pfizer and Moderna have developed vaccines that are capable of eliciting an immune response by employing a genetic code as their primary method of action. Different vaccines have been shown to be effective against the disease in question.

The doses of COVID-19 and Novavax vaccine are altered in a manner that is analogous to the way that influenza vaccinations are altered on an annual basis. In this way, fresh virus strains can be targeted more effectively.

SOURCE: USN